Literature DB >> 7548271

Trans-complementation of E1-deleted adenovirus: a new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses.

J L Imler1, A Bout, D Dreyer, A Dieterlé, H Schultz, D Valerio, M Mehtali, A Pavirani.   

Abstract

Treatment of cystic fibrosis by gene therapy will require the development of vectors capable of efficient and safe transfer of a functional cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to airway epithelia. To achieve this goal, replication-deficient (E1-) adenoviruses (Ad) are promising vectors. We have previously demonstrated efficient CFTR gene delivery to the airways of cotton rats and rhesus monkeys using a replication-deficient adenovirus, Ad-CFTR. Here, we have investigated an important safety issue, the interaction between the vector and wild-type virus which can provide the missing E1 function in trans. We show that Ad5 can mobilize the defective Ad-CFTR genome in vitro and in cotton rats. However, the extent of the complementation in vivo by wild-type virus is limited because no additional spreading or shedding of Ad-CFTR to trachea, lungs, and stools is elicited. To attenuate Ad-CFTR further, a mutation was introduced in the cis-acting regulatory sequences that control the encapsidation of the viral genome. We demonstrate that when cells are coinfected with wild-type virus and the new attenuated vector, the viral DNA containing the natural encapsidation sequences is preferentially packaged, leading to a rapid dilution of the recombinant virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548271     DOI: 10.1089/hum.1995.6.6-711

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  3 in total

1.  Replication-defective bovine adenovirus type 3 as an expression vector.

Authors:  P S Reddy; N Idamakanti; Y Chen; T Whale; L A Babiuk; M Mehtali; S K Tikoo
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 2.  Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.

Authors:  Joshua Del Papa; Robin J Parks
Journal:  Viruses       Date:  2017-01-19       Impact factor: 5.048

3.  Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.

Authors:  M J E Havenga; L Holterman; I Melis; S Smits; J Kaspers; E Heemskerk; R van der Vlugt; M Koldijk; G J Schouten; G Hateboer; K Brouwer; R Vogels; J Goudsmit
Journal:  Biotechnol Bioeng       Date:  2008-06-01       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.